ARIA: What Amyloid Antibody Brain Imaging Changes Mean

ARIA stands for amyloid-related imaging abnormalities, the swelling and small bleeds that show up on brain MRI scans in some people taking the newer anti-amyloid antibodies for early Alzheimer's disease, lecanemab and donanemab. It comes in two forms: ARIA-E, fluid or edema, and ARIA-H, tiny hemorrhages or iron deposits. Most cases appear in the first months of treatment and cause no symptoms, but a minority are serious, and rare deaths have occurred. The important development is that titration schedules, genetic testing, and MRI monitoring have all been revised on the basis of new evidence, and those changes measurably lower the risk.

What ARIA actually is

These drugs work by binding amyloid plaque so the immune system clears it from the brain. That clearance appears to stress small blood vessels, especially vessels already laden with amyloid, a condition called cerebral amyloid angiopathy. The result can be leaked fluid (ARIA-E) or microbleeds and surface iron staining (ARIA-H). A review in Brain Communications describes the underlying injury seen at autopsy in one lecanemab trial participant as severely damaged vessel walls with reactive immune cells, which fits the idea that pulling amyloid out of vessels temporarily weakens them.

The numbers give a sense of scale. In the pivotal lecanemab trial, roughly 12.6 percent of treated participants had ARIA-E and 17.3 percent had ARIA-H, as summarized in the same review. For donanemab in its phase 3 program, ARIA-E ran near 24 percent and ARIA-H near 31 percent. Most of this was picked up on scheduled scans, not because a person felt unwell. Symptomatic ARIA, when it happens, can look like headache, confusion, dizziness, or visual changes, which is one reason monitoring matters even when the person feels fine.

Genetics changes the odds

A single gene, APOE, strongly shapes risk. People who carry two copies of the APOE4 variant, called homozygotes, have by far the highest rates. In the lecanemab data, symptomatic ARIA-E occurred in about 9.2 percent of APOE4 homozygotes, compared with roughly 1.7 percent of people with one copy and 1.4 percent of non-carriers. The rate of severe imaging findings followed the same steep gradient. Because of this, the current FDA label advises testing APOE4 status before starting treatment, not to automatically exclude anyone, but so that the person and clinician can weigh the real magnitude of risk before the first dose.

Two baseline features push risk higher in a similar way: having several small hemorrhages already visible on MRI, and taking blood thinners. The Brain Communications review notes that two or more microhemorrhages at baseline roughly doubled the chance of developing ARIA-E, which is why baseline imaging and a careful medication review come before, not after, the decision to treat.

Slower titration lowered the risk in a trial

The most concrete piece of new evidence concerns how donanemab is started. Instead of jumping quickly to the full dose, a modified schedule redistributes the early doses so the ramp-up is gentler. In the TRAILBLAZER-ALZ 6 study, published in 2025 in a peer-reviewed Alzheimer's journal, this modified titration cut ARIA-E from about 23.7 percent to 13.7 percent at 24 weeks, roughly a 42 percent relative reduction, and from about 24.2 percent to 15.6 percent at 52 weeks, roughly a 35 percent reduction. Critically, amyloid was still cleared to a comparable degree, with adjusted mean plaque changes of around 71 and 72 centiloids in the two schedules. In plain terms, a slower start kept most of the benefit while removing a meaningful share of the swelling.

On the strength of that trial, the FDA approved an updated Kisunla (donanemab) label in 2025 adopting the modified titration for early symptomatic Alzheimer's, per Eli Lilly's announcement of the approval. This is a useful example of how a dosing question, not a new molecule, can move the safety needle.

Monitoring got earlier for lecanemab

For lecanemab, the change was to the imaging schedule rather than the dose. After reviewing serious cases, the FDA issued a drug safety communication recommending an additional, earlier monitoring MRI before the third infusion, on top of the scans already advised before the fifth, seventh, and fourteenth infusions. The reasoning is straightforward: because ARIA clusters early, an earlier look can catch it before it becomes symptomatic, at which point treatment is typically paused until the imaging settles. The review literature also emphasizes scan quality, recommending higher-field MRI with sequences sensitive to small bleeds so that findings are not missed.

How to read all of this

The honest picture is that these therapies remove amyloid and modestly slow decline, and that they carry a real, mostly manageable imaging risk that is now better characterized than it was at approval. None of the recent changes eliminate ARIA. What they do is stratify who is most vulnerable, start higher-risk regimens more gently, and look sooner. For anyone considering treatment, the practical questions are concrete: APOE4 status, baseline MRI findings, current use of blood thinners, and access to a center that can perform and interpret the monitoring scans on schedule. Those factors, taken together, describe the actual risk far better than any single headline percentage.

This article is educational and is not medical advice; decisions about anti-amyloid therapy belong to a person and their treating clinician, informed by individual imaging and genetic results.